Multilevel marketing company Rodan + Fields is facing a class action lawsuit claiming that its eye lash enhancing serum contains an ingredient that could cause eye problems, but the company failed to disclose to consumers about the side effects this ingredient poses.
The lawsuit, filed in the U.S. District Court in Oakland, California, claims that consumers who used Rodan + Fields Lash Boost eye serum “have experienced serious side effects including change(s) in iris color, eyelid drooping, itchy eyes, eye/lid discoloration, thinning and loss of eyelashes/loss of eyelash hair, eye sensitivity, eye infections, and vision impairment.”
The serum is touted to give users “the appearance of lush, longer-looking lashes.” But it also contains the chemical isopropyl cloprostenate, an analog of prostaglandin, which is used to treat eye conditions like glaucoma. An analog of prostaglandin is also found in the only Food and Drug Administration (FDA)-approved lash enhancer Latisse, but its maker Allergan fully discloses its risks to consumers.
Rodan + Fields’ Lash Boost is marketed as a cosmetic, where as Allergan’s Latisse is considered a drug and held to a higher regulatory standard. And while prostaglandins and analogs of this ingredient are banned from cosmetics in Canada, they are allowed in cosmetics sold in the U.S.
Even if Rodan + Fields is allowed to use the ingredient in its eye lash product, it should at least warn consumers of the risks, the lawsuit states.
Rodan + Fields generated more than $1.5 billion in sales in 2017, about $200 million of which was due to sales of Lash Boost, the company reported.
Source: CBS Money Watch